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PCARDIOVASCULAR GENOMIC MEDICINE
Redefining Risk in Acute Coronary
Syndromes Using Molecular Medicine
Saif Anwaruddin, MD,* Arman T. Askari, MD, FACC,* Eric J. Topol, MD, FACC†
Cleveland, Ohio; and La Jolla, California
Acute coronary syndromes represent a complex phenotype involving the interplay of many elements. The risk of
developing an acute coronary syndrome and related complications has been defined by variables such as age,
diabetes, smoking history, serum creatine phosphokinase, or electrocardiographic findings. However, in the past
5 years the wide-scale acceptance of a protein—troponin—has changed the diagnostic profile. With advances in
molecular medicine, this protein is a segue to a panel of molecular assays that will improve screening and tai-
lored intervention. We expound upon some of these factors and the potential they may carry in changing clinical
medicine. (J Am Coll Cardiol 2007;49:279–89) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.08.051n
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aoronary artery disease (CAD) is increasing in prevalence
nd is predicted to become the dominant cause of mortality
orldwide by 2020. A burgeoning body of literature exists
hat implicates inflammation as being central to atherogen-
sis and, ultimately, atherothrombosis (1). In fact, the inflam-
atory process appears to be more extensive than previously
hought and may involve multiple vulnerable plaques within
he coronary bed and, in many patients, other arterial trees
imultaneously (2). That an integral link among inflammation,
therogenesis, and atherothrombosis exists is fundamental to
nderstanding acute coronary syndromes (ACS). Translating
his understanding and the emerging concept of differential
enetic heritability between myocardial infarction (MI) and
therosclerosis (3) into the development of quantifiable molec-
lar risk factors in otherwise healthy, asymptomatic individuals
s a major goal for prevention.
As the mechanisms and pathways involved in the processes
f plaque rupture, thrombosis, and response to injury are
efined, a logical evolution would be to use this opportunity to
etter define risk of future events and complications. Use of
olecular markers of inflammation after ACS to predict the
ikelihood of recurrence or even appropriate response to ther-
py may facilitate targeted therapeutic strategies based on a
omprehensive molecular risk profile (4) rather than on demo-
raphic and clinical characteristics.
The goal of this review is to provide insight into the
omplex interactions between the inflammatory and cellular
echanisms involved in the pathogenesis of ACS and the
esponse to injury. The prognostic value of some of these
rom the *Department of Cardiovascular Medicine, The Cleveland Clinic, Cleve-
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alifornia. Dr. Topol is supported by National Institutes of Health grant P50
L077107. Cardiovascular Genomic Medicine Series edited by Geoffrey S. Gins-
urg, MD, PhD.p
Manuscript received March 15, 2006; revised manuscript received July 6, 2006,
ccepted August 28, 2006.ovel markers and relevant data on proposed therapeutic
nterventions will be addressed so that in time we can use
hese markers to prevent ACS events or, at least improve,
linical outcomes.
ndothelium
ompromise of endothelial integrity is felt to be fundamen-
al, not only to the initiation and progression of atheroscle-
otic disease, but also to the onset of ACS. Leukocytes are
elieved to contribute to direct endothelial damage in this
etting. Irrespective of the underlying contributor, endothe-
ial damage and dysfunction remain integral to atherogen-
sis and the development of an ACS.
irculating endothelial cells as a marker of panvascular
njury. Circulating endothelial cells are a marker of arterial
njury in vascular disease. Notably, significantly elevated
evels of circulating endothelial cells have been observed in
atients with ACS compared with those with stable angina
5). More recently, it was discovered that elevated levels of
irculating endothelial cells measured in patients within
8 h of an ACS independently predict subsequent short-
nd long-term outcomes (6).
ole of the subendothelial matrix von Willebrand factor
vWF) in ACS. Through the actions of a key component,
WF, on factor VIII activity, the matrix contributes to mod-
lation of the coagulation cascade and to the pathogenesis of
CS. Beyond its role in facilitating coagulation protein inter-
ction, vWF binds to subendothelial collagen via its A3
omain and initiates platelet adhesion via the glycoprotein
GP) 1b receptor (7). Experimental evidence suggests that
oth vWF and high shear stress may be responsible for platelet
ggregation in acute MI. Conversely, inhibition of the GP1b
eceptor from serum of patients with an acute MI or unstable
ngina by a vWF antibody results in reduced shear-induced
latelet aggregation (8). Ultimately, increased levels of vWF
t
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timal angiographic results and in-
creased adverse events across the
spectrum of ACS (9,10).
Platelets
The importance of platelets in
thrombosis and ACS is well es-
tablished. Through release of
various constituents, expression
of various receptors, and interac-
tions with leukocytes and the
endothelium, platelets function
as inflammatory mediators in pa-
tients with ACS (Fig. 1). Plate-
lets provide a pivotal link be-
ween inflammation and thrombosis in ACS.
D40 and CD40L. CD40 and CD40L have been found
n platelets and several other cell types in functional-bound
nd soluble (sCD40L) forms. Although many platelet-
erived factors have been identified, recent evidence sug-
ests that CD40L is actively involved in the pathogenesis of
CS. Through direct platelet-to-cell stimulation, most
otably the interaction between CD40L on activated plate-
ets and the CD40 receptor on endothelial cells, CD40L,
rives the inflammatory response. Such interactions facili-
ate increased expression of adhesion molecules on the
urface of endothelial cells and release of various stimulatory
hemokines. These events, in turn, facilitate activation of
irculating monocytes as a trigger of atherosclerosis (11).
Both CD40L and sCD40L contain separate domains
llowing for direct binding to the b3-receptor on plate-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CAD  coronary artery
disease
CRP  C-reactive protein
EPC  endothelial
progenitor cells
GP  glycoprotein
FLAP  5-lipoxygenase
activating protein pathway
LDL  low-density
lipoprotein
MI  myocardial infarction
Figure 1 Platelets: Key Mediators of Inflammation
CD40R  CD40 receptor; GP-1b  glycoprotein 1b receptor; IL-8  interleukin 8;
sCD40  soluble CD40; vWF  von Willebrand factor.ets. It has been suggested that this CD40L-platelet b3
eceptor interaction is important for stability of platelet-
ased thrombus (12). Stimulation of the b3 receptor is
nown to release sCD40L from within platelets (13) in
ddition to activating other platelets.
Beyond known proinflammatory and thrombotic prop-
rties of CD40L, experimental evidence suggests that
D40L-induced platelet activation leads to the produc-
ion of reactive oxygen and nitrogen species, which are
ble to prevent endothelial cell migration and angiogen-
sis (14). As a consequence of inhibiting endothelial cell
ecovery, the risk of subsequent coronary events may be
reater.
Clinical studies have supported the involvement of
D40L in ACS and the prognostic value in ACS popula-
ions. Levels of sCD40L have been shown to be an
ndependent predictor of adverse cardiovascular events after
CS (15) with increased levels portending a worse progno-
is (16,17). Importantly, specific therapeutic strategies have
hown to be beneficial in reducing risk associated with
CD40L (Table 1) (16–22). The interaction of sCD40L
nd glycoprotein IIb/IIIa receptor is important in throm-
osis and thrombus stability. Glycoprotein IIb/IIIa inhibi-
ors such as abciximab may provide benefit in this high-risk
opulation (17), with the caveat being the increased levels of
CD40L and potential worsening of the proinflammatory
tate and increased mortality seen with GP IIb/IIIa inhib-
tor underdosing (23,24).
These observations support the premise that platelet
ctivity is central to the proinflammatory and prothrombotic
tates in ACS. CD40L and sCD40L seem to link these
rocesses and underscore the need to identify those at
 monocyte chemoattractant protein-1; PSGL  P-selectin glycoprotein ligand;MCP-1
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January 23, 2007:279–89 Molecular Medicine in ACS Riskigher risk, who may benefit from more aggressive or even
ore selective therapy.
latelet-leukocyte interaction. The platelet serves as an
ntermediary between various cell types, most notably, the
eukocytes. P-selectin, expressed on the surfaces of both
ndothelium and activated platelets, and platelet-leukocyte
nteractions that occur via P-selectin and its natural ligand
-selectin glycoprotein ligand-1 (PSGL-1) both appear to
e important in thrombus generation.
Increased levels of soluble P-selectin have been shown to
redict future cardiovascular events in apparently healthy
omen (25), to predict those patients with an ACS at high
isk, and to potentially differentiate those patients with ACS
ersus stable angina (26). Despite these data, the utility of
-selectin as a marker of platelet activation in ACS remains
ncertain. A more sensitive marker of thrombosis in pa-
ients with unstable coronary syndromes may be platelet-
eukocyte aggregate levels (27).
eukocytes
he inflammatory responses leading to the disruption
f plaque and subsequent events in ACS is characterized
y a varied cellular presence. The relationship between
onocyte-derived macrophages and the pathogenesis of
therosclerotic coronary artery disease (CAD) has been well
tudied. In addition to macrophages, the importance of
ther leukocytes in these processes has become apparent.
Studies have suggested a relationship between leukocyto-
is and adverse cardiac events after acute MI (28) and ACS
29) has been demonstrated. The mechanisms by which
eukocytosis may lead to worse outcomes may include
roteolytic damage, leukocyte aggregation, microvascular
bstruction, infarct expansion, electrical instability, and
mpaired revascularization among others (30).
Dichotomizing cell types involved in atherogenesis com-
ared with the development of ACS is difficult. However,
he neutrophil, a hallmark of acute inflammation, has been
hought to be vital to acute plaque rupture with autopsy
pecimens of culprit lesions from acute MI patients dem-
nstrating higher concentrations of activated neutrophils
hat in those without ACS (31). At the other end of the
pectrum, infiltration of the atherosclerotic plaque with
onocytes and eventual uptake of oxidized low-density
ipoprotein (LDL) particles is thought to be central to
ormation of atherosclerotic plaque. Activated macrophages
re believed to facilitate ongoing inflammation present
ithin the plaque, and thus may be important in the
nitiation of ACS (Fig. 2).
eukocyte secretory products and ACS. Several leukocyte
ecretory products, including myeloperoxidase, monocyte
hemoattractant protein-1, various interleukins, matrix
etalloproteinases, pregnancy-associated plasma protein A,
eukotriene B4, hepatocyte growth factor, and interferon
amma, have been associated with atherogenesis, athero-thrombosis, ACS, and outcomes after ACS (Table 2)T M C S S V S F AC
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Molecular Medicine in ACS Risk January 23, 2007:279–8932–51). For example, myeloperoxidase, a powerful oxidant
eleased from both neutrophils and monocytes, has been
emonstrated in patients with coronary artery disease (52),
as been implicated in having a role in plaque destabiliza-
Figure 2 Leukocyte Secretory Products
HGF  hepatocyte growth factor; IFN-  interferon gamma; IL-18  interleukin-18
MMPs  matrix metalloproteinases; MPO  myeloperoxidase; NO  nitric oxide; V
elected Leukocyte Secretory Products and Possible Involvement i
Table 2 Selected Leukocyte Secretory Products and Possible I
Leukocyte Secretory Product
Myeloperoxidase Involved in low-density lipoprotei
Involved in plaque destabilizatio
Prognostic utility in those presen
Involved in post-MI remodeling (3
Monocyte chemoattractant protein-1 Essential for monocyte recruitme
Modulates inflammatory respons
Higher levels associated with wo
Interleukin (IL)-18 Induces production of IFN-, MM
Associated with “vulnerable plaq
Increased IL-18/IL-10 ratio corre
Matrix metalloproteinases (MMPs) MMP-2 and MMP-9 associated w
Elevated levels of MMP-2 and M
MMP-9 was associated with incr
Several isoforms, both cardiac a
Pregnancy-associated plasma protein-A
(PAPP-A)
Activates insulin-like growth fact
Circulating PAPP-A significantly h
Elevated levels an independent p
Several isoforms (both cardiac a
Hepatocyte growth factor Related to thrombus generation
Significantly higher levels of hep
thrombosis (47)
Antiapoptotic
Directly related to left ventricula
Interferon gamma (IFN-) Released from Th1 CD4 cells
Higher levels of Th1 CD4 cells
Activates monocytes/macrophagCS  acute coronary syndrome; MI  myocardial infarction.ion (50), and has been associated with a worse prognosis in
atients presenting with an ACS (51). Although the ma-
ority of these leukocyte secretory products link inflamma-
ion and atherothrombosis, their clinical applicability has
 low-density lipoprotein; MCP-1  monocyte chemoattractant protein-1;
 vascular cell adhesion molecule.
S
ement in ACS
Contribution to Atherogenesis/ACS
ation, nitric oxide breakdown, and endothelial homeostasis (32,33)
ith ACS (34,51)
)
therosclerosis, ACS, and postinfarct remodeling
tcome post ACS (37)
adhesion molecules
orphology (38,39)
trongly with risk of adverse events in those with ACS (40)
que instability (41)
een in patients with ACS (42)
risk of cardiovascular death in patients with ACS (43)
cardiac, exist
in patients with unstable coronary syndromes vs. those with stable angina (44)
or of 6-month major adverse cardiac events in patients with ACS (45)
cardiac forms) exist
ence of mast cells (46)
e growth factor demonstrated in patients with chest pain and evidence of acute
ion after MI (48)
n patients with unstable angina vs. those with stable angina or controls (49); LDL
CAMsn AC
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n (50)
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ncouraging data that emphasize the potential future utility
f some, if not all of these products.
rogenitor Cells
erived from bone marrow sources and peripheral mono-
uclear cells, circulating endothelial progenitor cells (EPCs)
ave been shown to possess several characteristics that may
acilitate the use of these cells as novel markers of endothe-
ial dysfunction as well as of ongoing tissue repair and/or
egeneration. Characteristics such as their pluriopotency,
bility to regenerate damaged endothelium, and the ability
o “home” to damaged or ischemic tissue and contribute to
eovascularization have elevated interest in these cells with
ovel prognostic and therapeutic goals in mind.
Endothelial progenitor cells represent a promising bi-
marker of endothelial dysfunction, one of the earliest
tages of atherogenesis. In a study of patients with risk factors
or CAD, reduced levels of EPCs correlated with higher
egrees of endothelial dysfunction. Conversely, augmenting
PC volume through mechanisms, including transplantation,
acilitates neovascularization and re-endothelialization and at-
enuates myocardial ischemia, supporting a role for EPCs in
aintaining the homeostasis of the endothelial wall. Assessing
or EPC levels may be more useful, given their correlation with
stablished risk factors for CAD (53), their correlation with the
resence of atherosclerosis (54), and with their prognostic
bility in patients with established CAD (55). However, levels
f circulating EPCs did not predict acute MI, suggesting a role
or EPCs in atherosclerosis progression, but not in acute
laque rupture.
Although a natural, EPC-mediated repair mechanism
hat exists after myocardial injury has been demonstrated
56), this process occurs at a rate that precludes any
eaningful functional recovery after MI. Experimental
vidence has suggested that delivery of cytokine-expanded
D34 EPCs via direct injection into the infarct border
one (57) may be able to augment the natural repair mecha-
isms and facilitate improvement in myocardial function.
hese observations highlight that a homing mechanism exists
ollowing myocardial injury, which, if harnessed, can contrib-
te to myocardial repair facilitated, in part, by EPCs.
Although EPCs represent a promising biomarker of
ndothelial dysfunction, they also maintain an ability to
articipate in the repair process. In a healthy state, there
s a role for progenitor cells in preservation of the
ndothelial wall. In states of endothelial dysfunction,
educed levels and functionality of EPCs and other
irculating progenitor cells may impair these abilities and
redispose to further injury. Manipulation of these pro-
enitor cells may provide a therapeutic strategy for
reating early stages of endothelial injury or preventing
dverse remodeling after MI. Cdipocytes
besity has been identified as a risk factor for the develop-
ent of the metabolic syndrome and subsequent cardiovas-
ular disease. Specifically, visceral adipose tissue has been
ited as the principal reservoir of adipocytes. Adipose tissue
s a metabolically active organ that contains blood vessels and
arious active cell types. Acting through various endocrine and
aracrine mechanisms, the relevance of adipose tissue to
ardiovascular disease stems from its proinflammatory effects.
besity, especially that which is associated with increased
aist-to-hip ratio or increased visceral fat, leads to the up-
egulation of various intercellular adhesion molecules,
-selectin, C-reactive protein (CRP), interleukin-6, tumor
ecrosis factor-, interleukin-18, tumor necrosis factor recep-
ors, and plasminogen activator inhibitor-1, among others, are
hought to result in a proinflammatory state that contributes to
therogenesis. Suppression of adiponectin, a protective adipo-
ine, also appears to result from obesity.
Although adipocytes produce and secrete a variety of
ther factors, much is being learned about many of these
actors and any relationship to coronary artery disease and
CS. Other examples include the transcription factor
ATA2, resistin, CRP, serum amyloid A3, and leptin.
lthough these represent novel markers and may provide
aluable insight with regard to atherosclerotic disease re-
ated to obesity, only CRP has been extensively studied in
he context of coronary artery disease (Table 3) (58–80).
RP. C-reactive protein is an acute phase reactant pro-
uced primarily by the liver in response to cytokines such as
nterleukin-6. It has gained attention not only as a marker of
nflammation and cardiovascular risk but as an active par-
icipant in the process (81). C-reactive protein adds value
eyond traditional cardiovascular risk factors such as LDL
n predicting the risk of MI, stroke, need for revasculariza-
ion, or death from cardiovascular causes (82). The signif-
cance of CRP is that it highlights the relationship between
ngoing inflammation and future cardiac events. In those
ith unstable angina, discharge CRP levels predicted long-
erm risk of recurrent events (83).
Beyond prognostic value, evidence supports the direct
nvolvement of CRP in the development of atherosclerotic
laque. C-reactive protein, identified in atherosclerotic
laque, has been shown to facilitate macrophage uptake of
DL particles (84) and to regulate both macrophage recruit-
ent (85) and vascular adhesion molecule expression (86).
C-reactive protein has become an attractive target for
edical therapy in coronary atherosclerosis (Table 4) (87–
4). Therapeutic strategies in ACS have focused on modi-
able risk factors, but none have focused on inflammation
er se. It still remains to be seen what effect specifically
argeting CRP will have upon hard clinical end points. A
ecent study in mice with experimental MI showed that CRP
nhibition could markedly reduce infarct size (95). Although
tatin therapy has been touted for its ability to reduce levels of
RP (87–89,91) only now are studies under way examining
AA
c
p
f
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Table 3 Adipocyte-Related Secretory Products: Relationship to Cardiovascular Disease
Secretory
Product Functional Role
Rationale for Involvement in
Atherosclerosis Clinical Evidence Comments
Adiponectin Important role in lipid and
carbohydrate metabolism
Modulates action of insulin
Prevents lipid uptake by macrophages
 inhibits transformation into foam
cells (58)
Acts to increase TIMP-1 expression in
macrophages in vitro (59)
Affects expression of various cellular
adhesion molecules by affecting
NF-B signaling (60,61)
Levels correlate inversely with future
risk of CV events and CRP
levels (62)
Males with type II DM, 5-yr risk of
fatal/nonfatal CAD inversely
correlates with adiponectin (63)
Nested case control data from
HPFS, adiponectin inversely
correlates with 6-yr risk of fatal/
nonfatal CAD (64)
Lower levels of adiponectin in those
with established CAD vs.
controls (65)
Acute drop in adiponectin levels
observed after AMI (66)
Likely to possess protective effects
in relation to atherosclerotic
disease. This needs to be further
defined. However, it holds
prognostic value in selected
populations.
PAI-1 Functions to inhibit
plasminogen activation
and results in a balance
favoring a prothrombotic
state and may serve as a
marker of impaired
fibrinolysis
Prothrombotic
PAI levels are often increased in
vascular disease, including DVT
and AMI
Balance between PA/PAI-1 is affected
in states such as obesity and DM
Small clinical study showing TnT and
PAI-1 add prognostic information
in the setting of ACS (67)
In STEMI patients, acute rise in
PAI-1 during first 24 hrs predicts
30-day mortality and risk for
developing CHF (68)
May potentially serve as a link
between inflammation and
thrombosis. It may provide
adipocytes a mechanism by
which to modulate the
thrombotic state.
VEGF Angiogenic factor Levels of visceral adipose tissue
correlate with VEGF levels
VEGF-induced angiogenesis may
contribute to atherosclerotic
lesions (69)
In experimental models, VEGF has
been shown to hasten the
progression of atherosclerotic
plaque (70,71)
Suggestions have been made about
neovascularization being a factor in
plaque instability and rupture (72)
VEGF appears to modulate effect of
angiotensin II-mediated
inflammation (73)
Treatment with statin therapy has
been shown to reduce VEGF levels
in those with established coronary
atherosclerosis (74)
The significance of angiogenesis in
the context of coronary artery
disease remains controversial.
There is phase I clinical trial
data which show symptomatic
benefit of VEGF via direct
myocardial injection in those
with refractory angina.
IL-6 Pro-inflammatory
Increases production of
CRP in the liver
Leads to production of CRP, a marker
known to be associated with risk of
future CV events
Has been shown to decrease
lipoprotein lipase activity
Elevated IL-6 levels in unstable
angina patients predicted
complicated in-hospital
course (75)
By mediating production of CRP, in
addition to affecting the
production of vascular cellular
adhesion molecules and
affecting coagulation, IL-6 may
modulate many of the events
that promote atherosclerotic
disease.
TNF- Has a role in obesity-related
insulin resistance
A cytokine involved in many
proinflammatory disease
states
In obesity, expression also increased
on the surface of adipocytes
Affects endothelial function by
modulating expression of cellular
adhesion molecules through
NF-B (76)
Increases MMP activity (77)
Inhibition of TNF- in apoE knockout
mice reduces disease
progression (78)
Large-scale clinical data lacking.
However, small studies have
shown elevated levels of TNF- in
unstable coronary syndromes (79)
Although much experimental
evidence suggests a potential
mechanistic role for this
adipocyte product in
atherosclerosis and acute
coronary syndromes, clinical
data supporting its involvement
are sparse.
Resistin Has been shown to induce
insulin resistance in
rodents
Adipocyte product
Levels correlate with other
inflammatory markers such as IL-6
Plasma resistin levels predict
coronary atherosclerosis in
humans (based on coronary artery
calcification as an index) (80)
Much more information is
necessary to delineate the role
for resistin in humans, especially
in linking inflammation and
atherosclerosis.
CS  acute coronary syndrome; AMI  acute myocardial infarction; apo  apolipoprotein; CAD  coronary artery disease; CHF  congestive heart failure; CRP  C-reactive protein; CV 
ardiovascular; DM  diabetes mellitus; DVT  deep venous thrombosis; HPFS  health professionals; IFN-  interferon gamma; IL-6  interleukin-6; NF-b  nuclear factor kappa B; PA 
lasminogen activator; PAI-1  plasminogen activator inhibitor-1; STEMI  ST-segment elevation myocardial infarction; TIMP-1  Tissue inhibitor of metalloproteinase 1; TNF-  tumor necrosis
actor-alpha; TnT  troponin T; VEGF  vascular endothelial growth factor.
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January 23, 2007:279–89 Molecular Medicine in ACS Riskhe effects of various therapeutic modalities upon CRP levels as
marker of clinical cardiovascular risk (93,94).
It is apparent that inflammatory status is a variable that
eeds to be strongly considered. Whether currently available
herapy will reduce inflammation and improve clinical end
oints has yet to be determined. Nevertheless, CRP pro-
ides valuable insight regarding the link between inflamma-
ion, CAD, and ACS.
enetic Risk, Molecular Risk
actors, and Clinical Medicine
enetic predisposition toward the development of MI is a
oncept that is only bluntly defined by traditional risk
actors such as hypertension or hyperlipidemia. This com-
on complex trait with extensive gene-environment and
ene-gene interactions is in the early phase of being
enomically unraveled. Complexity of the process is re-
ected in the number of single nucleotide polymorphisms.
or example, the inhibition of the recently identified
-lipoxygenase activating pathway with a 5-lipoxygenase
ctivating protein pathway (FLAP) blocker in patients with
gain-of-function FLAP or leukotriene A4 haplotype has
ffect of Medical Therapy on CRP
Table 4 Effect of Medical Therapy on CRP
Study Patients (n) Design
PRINCE (87) 2,013 in primary prevention
cohort
1,375 in secondary
prevention cohort
Community-based, prospec
double-blind, randomized
CARE substudy (88) 391 patients from CARE
who developed recurrent
coronary events vs.
controls
Nested case control study
CARE, a randomized, do
blind, placebo-controlled
PROVE IT–TIMI-22
substudy (89)
3,745 patients with ACS Substudy of PROVE IT–TIM
a randomized 2  2 fac
designed trial
REVERSAL (90) 657 patients randomized
to 40 pravastatin or
80 atorvastatin
Double-blind, randomized a
control multicenter trial
AFCAPS/TexCAPS
substudy (91)
5,742 patients randomized
to lovastatin vs. placebo
Substudy of double-blind,
randomized, placebo-con
study
Haffner et al. (92) 357 patients randomized to
rosiglitazone vs. placebo
Frozen blood samples anal
from type II diabetics wh
participated in a 26-wee
randomized, double-blind
placebo-controlled trial u
rosiglitazone
JUPITER (93,94) Target population of 15,000
males  55 and females
 65 years of age
Randomized, double-blind,
placebo-controlled trial o
rosuvastatin among thos
elevated CRP and low LD
CS  acute coronary syndrome; AFCAPS/TexCAPS  Air Force/Texas Coronary Atherosclerosi
ardiovascular; IVUS  intravascular ultrasound; JUPITER  Justification for the Use of Statins in P
ipoprotein; MI  myocardial infarction; MMP  matrix metalloproteinase; pop  population; PRI
ravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarctioeen shown to reduce the degree of inflammation as peasured by various proinflammatory biomarkers, including
RP and leukotriene B4. Similarly, specific variants of
CSK-9 and USF-1, which affect lipoprotein handling,
ave been shown to provide marked protection from ACS
vents (96–99). This is a promising example of how such
pecific genomic information could facilitate individualized
revention.
With high-throughput genotyping of 500,000 key
arker single nucleotide polymorphisms, the ability to
dentify the susceptibility factors for ACS such as FLAP or
eukotriene A4 is greatly enhanced. High-throughput se-
uencing tools and microarrays will allow for examination
nd comparison of thousands of genes at once. The potential
xists for developing profiles of risk based on genetic informa-
ion. Ginsburg et al. (100) discuss the value of personalized
ardiovascular medicine using not only large-scale genetic
rofiles but also gene products in revolutionizing the scope of
linical practice. Improved diagnostic sensitivity and refined
rognostic value in combination with a tailored therapeutic
pproach would be the proposed outcome.
More and more genes and gene products are being
onsidered as being valuable in providing information about
Outcome Comments
Pravastatin resulted in a statistically
significant reduction in CRP both
at 3 and 6 mos vs. placebo
Effect of statin therapy on CRP was
independent of LDL level
Pravastatin resulted in a significant
lowering of CRP; statin therapy
resulted in a reduction in relative
risk of further coronary events
Demonstrates anti-inflammatory
effects of statin therapy;
Possibility exists that pravastatin
therapy may reduce risk of
coronary events by controlling
inflammation
Lower CRP after statin therapy in this
group resulted in better clinical
outcomes
Effect was noted to be independent
of LDL cholesterol
High-dose atorvastatin reduced CRP
more than pravastatin;
furthermore, high-dose therapy
resulted in reduced atherosclerosis
progression by IVUS
High-dose atorvastatin therapy
reduced progression of
atherosclerosis by IVUS, not a
clinical end point trial
Long term lovastatin therapy was
effective in primary prevention in
those with elevated CRP
Again, effect was independent of
lipid profile changes
Rosiglitazone therapy reduced MMP
and CRP levels, suggesting a
potential beneficial effect upon
cardiovascular risk
No hard clinical end points were
examined
Will evaluate primary end points of
MI, stroke, UA, CV death, or
revascularization
Hopes to answer whether statin
therapy will reduce the risk of CV
events in those with elevated
CRP as a surrogate for
inflammation
ntion Study; CARE  Cholesterol and Recurrent Events Study; CRP  C-reactive protein; CV 
Prevention—Can CRP be Used to Target Statin Therapy in Primary Prevention; LDL  low-density
Effect of Statin therapy on C-RP: Pravastatin Inflammation/CRP Evaluation; PROVE IT–TIMI-22 
EVERSAL  Reversal of Atherosclerosis w/ Aggressive Lipid Lowering; UA  unstable angina.tive
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tility must be questioned in dedicated clinical trials. A
tandardized panel of markers used to assess inflammation,
laque vulnerability, and other features may become part of
linical practice, but the selection of which markers to use
emains undecided, especially as the selection pool grows in
ize and complexity. Most of the markers that have been
iscussed have not yet been examined concurrently in large-
cale clinical epidemiologic studies. Transitioning these mark-
rs directly into clinical practice without sufficient data stands
nly to create confusion. Furthermore, of the markers that hold
romise in clinical medicine, there is still much to be learned
bout specific assays, measurement characteristics, and more
recise pathophysiologic definitions. sCD40L is an excellent
xample of this as sample processing and temperature were
ound to affect measurements (101)—despite our current
nowledge, our understanding still remains limited.
Although the discovery of such markers and subsequent
tudies proving association with ACS will likely continue to
ake place at an accelerated pace, the rate-limiting step should
nvolve a rigorous process of systematically evaluating these
arkers prior to transitioning into clinical practice. This would
nclude reproducibility in large populations, a scrutiny of assay
ethods, cost effectiveness appraisals, an assessment of practi-
ality, and determination of whether value is added beyond
urrent methods of risk stratification.
onclusions. It is apparent that a myriad of cellular and
olecular mediators involved in the proinflammatory and
rothrombotic phases of atherosclerosis and ACS exist.
hat determines any individual’s clinical manifestations
ay reflect the interplay of inflammatory components,
nvironmental factors, and genetic susceptibility. Although
Figure 3 A Model of Risk Stratification Based on a Representa
ACS  acute coronary syndrome; CRP  C-reactive protein; EPC  endothelial pro
IL  interleukin; LTA4  leukotriene A4 pathway; MMPs  matrix metalloproteinas
nancy-associated plasma protein A; sCD40L  soluble CD40 ligand; TNF-  tum
brand factor.ur understanding of the inflammatory processes is only bow expanding, we are just scratching the surface with
egard to genetic susceptibility in acute coronary syndromes.
What remains wholly apparent, however, is the complex-
ty of this disease process. It is no wonder, then, that many
lements have been individually identified, characterized,
nd studied in the clinical setting in an effort to understand
t least one potential pathway. Although no one entity has
ver been found to be the holy grail of the ACS, the
nderstanding of the complex interplay between these
omponents seems to be most important.
In time, risk assessment may take the form of an
valuation of multiple molecular factors using a comprehen-
ive pan-arterial analysis of carefully selected candidate
enes and molecules that reflect the variety of cellular and
olecular components actively involved in the pathogenesis
f clinically apparent disease (Fig. 3).
Although using such a panel for disease risk stratification
emains an objective, monitoring disease activity and pur-
uing individualized disease prevention are possible out-
rowths of this work. In those with known disease, monitor-
ng for evidence of ongoing inflammation, endothelial
ysfunction, or platelet activation may help to identify those at
igher risk requiring more intensive or more specific therapy to
vert future events. Ultimately, real promise may turn out for
rimary prevention whereby the use of a panel of molecular
arkers and candidate genes may identify a particular segment
f the population at risk for clinically significant CAD,
therwise undetectable. Screening for early evidence of endo-
helial dysfunction, up-regulation of inflammation, thrombo-
is, or genetic susceptibility will likely provide a new more
recise assessment of risk for future cardiovascular disease
anel of Molecular and Genetic Factors
r cell; FLAP  5-lipoxygenase activating protein pathway; fn  platelet function;
PO  myeloperoxidase; PAI-1  plasminogen activator inhibitor; PAPP-A  preg-
rosis factor alpha; VEGF  vascular endothelial growth factor; vWF  Von Wille-tive P
genito
es; M
or neceyond traditional clinical risk factors.
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